New chemo formula aims to reduce side effects in lymphoma transplant

NCT ID NCT06915246

First seen Apr 01, 2026 · Last updated May 13, 2026 · Updated 4 times

Summary

This study tests a new form of the chemotherapy drug carmustine (called VI-0609) that doesn't contain ethanol, compared to the standard version (BiCNU) which does. Both are used as part of the BEAM conditioning regimen before a stem cell transplant in adults with Hodgkin or non-Hodgkin lymphoma. The goal is to see if the ethanol-free version causes fewer infusion-related side effects. About 49 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • City of Hope Atlanta

    RECRUITING

    Newnan, Georgia, 30265, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • City of Hope Chicago

    RECRUITING

    Zion, Illinois, 60099, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • City of Hope National Medical Center

    RECRUITING

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • City of Hope Phoenix

    RECRUITING

    Goodyear, Arizona, 85338, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.